iHeartMedia, Inc. to Report Quarterly Financial Results on August 11, 2025
A live audio webcast of the call will be available on the Investors homepage of iHeartMedia's website ( https://investors.iheartmedia.com/) beginning at 4:30 p.m. (ET) on August 11th. The conference call can also be accessed by dialing (888) 596-4144 (domestic) or +1 646 968-2525 (international) using PIN number 8885116 followed by # key. Please call at least five minutes in advance to ensure that you are connected prior to the call.
An audio replay of the call will be available beginning at 7:30 p.m. (ET) on August 11th in the Events & Presentations section of iHeartMedia's Investors home page, and at (800) 770-2030 (domestic) or +1 609 800-9909 (international) using PIN number 8885116 followed by # key. The audio replay will be available for a period of thirty days.
The earnings release and any other information related to the call will be accessible on the Investors home page of iHeartMedia's website.
About iHeartMedia, Inc.
iHeartMedia, Inc. [Nasdaq: IHRT] is the leading audio media company in America, reaching over 250 million people each month. It is number one in both broadcast and digital streaming radio as well as podcasting and audio ad tech, and includes three business segments: The iHeartMedia Multiplatform Group; the iHeartMedia Digital Audio Group; and the Audio and Media Services Group. Visit iHeartMedia.com for more company information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
29 minutes ago
- Toronto Star
Aura Announces Q2 2025 and H1 2025 Financial and Operational Results
ROAD TOWN, British Virgin Islands, Aug. 05, 2025 (GLOBE NEWSWIRE) — Aura Minerals Inc. (NASDAQ: AUGO) (TSX: ORA) (B3: AURA33) ('Aura' or the 'Company') announces that it has filed its audited consolidated financial statements and management discussion and analysis (together, 'Financial and Operational Results') for the period ended June 30, 2025. The full version of the Financial and Operational Results can be viewed on the Company's website at on SEDAR+ at or on SEC 'In Q2, we achieved another record-high Adjusted EBITDA of US$106 million, driven by higher production and gold price of US$3,185 / Oz, bringing our last twelve months (LTM) Adjusted EBITDA to US$344 million at an average gold price of US$2,812 / Oz. Additionally, Aura reached significant milestones, including the publication of the Preliminary Economic Assessment (PEA) for Era Dorada, the signing of a purchase agreement for MSG, and a successful IPO on Nasdaq. We also approved our quarterly dividend payment, delivering a 7.4% yield return to our shareholders over the LTM, inclusive of share buybacks. Looking ahead, we expect commercial production at Borborema, the completion of the MSG acquisition in Q3, and to meet our production and cost guidance for the year.' Commented Rodrigo Barbosa President and CEO of Aura.
Globe and Mail
29 minutes ago
- Globe and Mail
ITRM Reports Results
Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, while general and administrative costs rose 121.1%, Research and development expenses were $1.0 million compared to $2.1 million for the same period in 2024, while general and administrative expenses increased from $1.9 million to $4.2 million, reflecting launch preparations. Cash runway is projected into 2026, with a $20.0 million milestone payment to Pfizer deferred until October 2029, reducing near-term cash pressure. These 10 stocks could mint the next wave of millionaires › Iterum Therapeutics Plc (NASDAQ:ITRM), an infectious disease biopharma company preparing to launch a new oral antibiotic for urinary tract infections, reported its results for the second quarter of 2025 on August 5, 2025. The key news in the release was its continued lack of revenue as it gears up for the first commercial sales of ORLYNVAH™, coupled with a larger operating loss driven by a jump in general and administrative costs. Reported non-GAAP loss per share came in at ($0.13), which was $0.02 below analyst expectations for non-GAAP EPS, while revenue (GAAP) was in line with estimates at zero. Overall, the quarter marked a pivotal transition phase, with significant expense increases for launch readiness but progress made in manufacturing, patent protection, and financial runway extension. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Company Overview and Recent Focus Iterum Therapeutics focuses on bringing new solutions to patients with serious infectious diseases, especially those where antibiotic resistance limits treatment options. Its most advanced product is ORLYNVAH™, an oral antibiotic tablet aimed at treating uncomplicated urinary tract infections (uUTIs), particularly cases caused by bacteria resistant to existing drugs. The company's recent efforts have targeted three areas: preparing for the first commercial launch of ORLYNVAH™, reinforcing patent protection to secure long-term value, and managing its financial position. Key factors for success include establishing commercial and distribution partnerships, navigating the regulatory landscape, and balancing operating costs to extend cash resources through launch. Highlights From the Quarter: Financial and Operational Developments The company reported no revenue in the quarter, which matches its pre-launch status and analyst forecasts. Non-GAAP EPS was a loss of $0.13, steeper than the anticipated $0.11 non-GAAP loss, largely due to a substantial increase in general and administrative (G&A) spending. This rise in G&A costs—from $1.9 million in the prior-year quarter to $4.2 million (GAAP)—was linked to investments in pre-commercialization work, such as market research and promotional strategy development. Research and development (R&D) expenses dropped sharply to $1.0 million (GAAP). Research and development expenses were $1.0 million compared to $2.1 million for the same period in 2024, as clinical trial activity wound down following the conclusion of the REASSURE Phase 3 trial for ORLYNVAH™. Total operating expenses (GAAP) climbed 39.1% year over year, to $5.5 million, with the G&A increase outweighing the R&D savings. The net loss, using Generally Accepted Accounting Principles (GAAP), was $6.5 million, greater than the $5.0 million GAAP net loss in Q2 2024. Operationally, Iterum put in place agreements to ensure manufacturing supply for ORLYNVAH™'s launch and expanded its intellectual property portfolio, securing a Canadian patent for its core antibiotic combination. The appointment of a new chief commercial officer signaled increased focus on market entry and execution. Iterum also finalized a commercialization agreement with EVERSANA to support U.S. sales, marketing, and distribution. The balance sheet reflected both ongoing cash burn and steps to strengthen the company's financial position. Cash and equivalents totaled $13.0 million as of June 30, 2025, and management indicated this is sufficient to support operations, including the commercial launch, into 2026, based on cash and cash equivalents as of March 31, 2025, together with amounts raised under the Registered Direct Offering and at-the-market offering program. Of note, a $20.0 million milestone payment due to Pfizer was deferred until October 2029, easing the company's near-term liquidity needs. At the end of the quarter, the company reported approximately 44.7 million shares outstanding, up meaningfully as new shares were issued to fund operations. About the Product Pipeline and Intellectual Property ORLYNVAH™ is an oral antibiotic tablet, or penem, formulated specifically for treating uncomplicated urinary tract infections in adult women when other oral options are limited or ineffective. The product stands out as the only oral penem approved by the U.S. Food and Drug Administration (FDA) and the first branded oral antibiotic in over 25 years for this indication. Iterum has built a robust patent portfolio, now extending to December 2039 in Canada, which helps protect its sulopenem/probenecid combination from generic competition. Looking Ahead: Management Outlook and Investor Watchpoints For FY2025 and beyond, management expects the existing cash balance, together with recent capital raises, to cover operational and commercialization activities into 2026. No detailed revenue or profit guidance was provided, as focus remains on completing the U.S. launch of ORLYNVAH™ in late August and laying the foundation for future sales. Other areas to monitor include expense trends—particularly in G&A as launch operations build out—and potential further equity raises given heightened cash needs ahead of revenue generation. Competitive developments will also be important, especially as other new antibiotics, such as from GlaxoSmithKline, move closer to market entry. ITRM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
National Post
29 minutes ago
- National Post
Carney vows $1.2 billion bailout for lumber sector hit by Trump tariffs
Prime Minister Mark Carney promised as much as $1.2 billion to shore up Canada's lumber industry, which has been hit hard by U.S. duties that are about to significantly increase. Article content Carney said Tuesday that up to $700 million in loan guarantees will help forestry companies of all sizes maintain and restructure their operations. He also pledged $500 million in grants and contributions for product development and market diversification. Article content Article content Article content 'Canada does not dump lumber into the United States, and we will continue to make the case that these current and proposed duties are unjustified,' Carney said in West Kelowna, B.C. Article content Article content 'We are a vital supplier to our southern neighbour, representing around a quarter of the U.S. market and helping to keep down the costs of American homes.' Article content The dispute between the U.S. and Canada over softwood lumber stretches back decades, with the U.S. periodically imposing duties to counteract what it claims are unfair Canadian government subsidies. Article content The U.S. Commerce Department is expected on Friday to conclude hiking duties on Canadian softwood to about 35 per cent from a previous total of 14.4 per cent. That's a combination of anti-dumping and countervailing duties. Article content U.S. President Donald Trump has escalated the fight even further, ordering an increase to U.S. lumber production and an investigation of the national security risk of lumber imports. The probe is under Section 232 of the Trade Expansion Act, which Trump has already used to place new tariffs on steel, aluminum and copper. Article content Article content Canada shipped $40.3 billion of forest products and building and packaging materials to the U.S. last year, its fifth-largest category of exports to its largest trading partner. Article content Article content Carney said his government would launch its promised homebuilding agency, called Build Canada Homes, in the fall, which will prioritize Canadian lumber, steel and aluminum in construction. Article content It will also require companies contracting with the federal government to source domestic well, the government will draft new initiatives to diversify international markets for Canadian lumber, along with retraining programs for workers, he said. Article content Canada has long denied the U.S. claim that it sets artificially low 'stumpage rates,' fees sawmills pay to provinces to harvest timber from government-owned forests. Article content The World Trade Organization in 2020 largely backed Canada's argument that U.S. levies were unfair. Article content But that stance may be softening. Last month, British Columbia Premier David Eby told Bloomberg News that some Canadian leaders are open to a quota on softwood lumber exports to the U.S. in order to resolve the dispute.
